α<sub>1A </sub>/α<sub>1D</sub>肾上腺素能受体阻断剂治疗输尿管下段小结石152例临床观察

王小磊; 蒲建军; 李黎明

α_1A/α_1D肾上腺素能受体阻断剂治疗输尿管下段小结石152例临床观察

- 1. 天津市塘沽区海洋石油总医院泌尿外科(天津, 300452);
- 2. 天津医科大学总医院泌尿外科

详细信息

通讯作者: 王小磊,E-mail:wangxiaolei80@sohu.com

中图分类号: R693

收稿日期: 2011-05-13

Corresponding author: , E-mail: wangxiaolei80@sohu.com

Received Date: 13 May 2011

摘要

摘要: 目的：观察α_1A/α_1D受体阻断剂治疗输尿管下段0.4~1.0 cm结石的临床疗效。方法：选取门诊输尿管下段0.4~1.0 cm之间的结石患者152例，随机分为两组：其中对照组共72例，给予口服抗胆碱药山莨菪碱片10 mg tid，2周，同时饮水>2 000 ml/d；治疗组共80例，采用α_1A/α_1D肾上腺素能受体阻断剂坦索罗辛（哈乐）0.4 mg，qd，2周，同时饮水>2 000 ml/d。结果：对照组结石排出率为44.4%（32/72），平均排出时间（7.9±2.5） d，强效镇痛剂使用率19.4%（14/72）；治疗组结石排出率为77.5%（62/80），平均排出时间（4.7±2.0） d，强效镇痛剂使用率6.25%（5/80）；两组结石排出率、排出时间、强效镇痛药使用率比较差异有统计学意义（P<0.05）。结论：α_1A/α_1D受体阻断剂治疗输尿管下段0.4~1.0 cm之间结石能明显提高结石排出率，有效缩短排出时间，减少强效镇痛药的使用率，比抗胆碱药物山莨菪碱更有效。
- 输尿管下段结石 /
- 坦索罗辛 /
- 山莨菪碱

HTML全文

参考文献(15)

[1]	米华,邓耀良. 中国尿石症的流行病学特征[J]. 中华泌尿外科杂志,2003,24(10):715-716.
[2]	WOLF J S J R. Treatment selection and outcomes:ureteral calculi[J]. Urol Clin N Am,2007,34:421-430.
[3]	罗勇,冀荣俊,孙超,等. 坦索罗辛联合排石冲剂治疗输尿管下段结石疗效观察[J]. 安徽医药,2009,13(3):313-314.
[4]	PORPIGLIA F,CHIGNONE G,FIORI C,et al. Nifedipine versus tamsulosin for the management of lower ureteral stones[J]. J Urol,2004,172:568-571.
[5]	CERVENÀKOV I,FILLO J,MARDIAK J,et al. Speedy elimination of ureterolithiasis in lower part of ureters with the alphal-blocker tamsulosin[J]. Int Urol Nephrol,2002,34:25-29.
[6]	MORITA T,WADA I,SAEKI H,et al. Ureteral urine transport:changes in bolus volume,peristaltic frequency,intraluminal pressure and volume of flow resulting from autonomic drugs[J]. J Urol,1987,137:132-135.
[7]	AL-ANSARI A,AL-NAIMI A,ALOBAIDY A,et al. Efficacy of tamsulosin in the management of lower ureteral stones:a randomized double-blind placebo-controlled study of 100 patients[J]. Urology,2010,75:4-7.
[8]	GRIWAN M S,SINGH S K,PAUL H,et al. The efficacy of tamsulosin in lower ureteral calculi[J].Urol Ann,2010,2:63-66.
[9]	SUN Y H,LIU Z Y,ZHANG Z S,et al. Long-term efficacy and safety of tamsulosin hydrochloride for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia:data from China[J].Chin Med J,2011,124:56-60.
[10]	MOKHLESS I,ZAHRAN A R,YOUSSIF M,et al. Tamsulosin for the management of distal ureteral stones in children:A prospective randomized study[J]. J Pediatr Urol, 2011, Nov 16.
[11]	PORPIGLIA F,FIORI C,GHIGNONE G,et al. A second cycle of tamsulosin in patients with distal ureteric stones:a prospective randomized trial[J].BJU Int,2009,103:1700-1703.
[12]	ZHOU S G,LU J L,HUI J H. Comparing efficacy of α_1D-receptor antagonist naftopidil and α_1A/D-receptor antagonist tamsulosin in management of distal ureteral stones[J].World J Urol,2011,29:767-771.
[13]	PORPIGLIA F,VACCINO D,BILLIA M,et al. Corticosteroids and tamsulosin in the medical expulsive therapy for symptomatic distal ureter stones:single drug or association[J]? Eur Urol, 2006, 50:339-344.
[14]	任小刚,刘树硕,裘顺安,等. 坦索罗辛和山莨菪碱治疗输尿管远端结石的疗效比较[J]. 中国中西医结合外科杂志,2008,14(4):333-334.
[15]	袁耀宇,林亚,刘世雄,等. α₁受体拮抗剂与胆碱能受体拮抗剂治疗输尿管下段结石的比较[J]. 中国医师进修杂志,2009,32(20):73-75.